Showing Results for
- Academic Journals (11)
Search Results
- 11
Academic Journals
- 11
- Search Terms:ISSN: 14655411AndISSN: 1465542XAndVolume Number: 12AndIssue Number: 6AndStart Page: R110AndDate: 2010 Revise Search
- 1From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedAuthor(s): Vincent K Tuohy1 In a recent issue of Breast Cancer Research , Watson and Gusterson wrote a viewpoint article [1] about our strategy for developing a prophylactic breast cancer vaccine [2]. The authors...
- 2From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedImmunohistochemistry is the most common method for companion diagnostic testing in breast cancer. The readings for estrogen receptor, progesterone receptor, and Her2 directly affect prescription of critical therapies....
- 3From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedRecent evidence suggests that a rare-cell population with a stem cell phenotype maintains breast tumors. Therefore, to devise breast cancer therapies that are more effective, we need to understand the unique biology of...
- 4From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedIntroduction Current attempts to identify genetic modifiers of BRCA1 and BRCA2 associated risk have focused on a candidate gene approach, based on knowledge of gene functions, or the development of large genome-wide...
- 5From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedTreatment options for women with early-stage breast cancer have never been better, and the addition of bisphosphonates to adjuvant therapy is a valuable new tool capable of substantially improving clinical outcomes for...
- 6From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedIntroduction The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1...
- 7From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedA substantial proportion of lymph node-negative patients who receive adjuvant chemotherapy do not derive any benefit from this aggressive and potentially toxic treatment. However, standard histopathological indices...
- 8From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-Reviewed[beta]-Catenin plays important roles in mammary development and tumorigenesis through its functions in cell adhesion, signal transduction and regulation of cell-context-specific gene expression. Studies in mice have...
- 9From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedIntroduction Immunohistochemistry of primary breast cancer is routinely used to guide changes in therapy at the time of relapse. Retrospective reviews suggest that the estrogen receptor (ER), progesterone receptor...
- 10From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedBreast cancer frequently metastasizes to the skeleton, interrupting the normal bone remodeling process and causing bone degradation. Osteolytic lesions are the end result of osteoclast activity; however, osteoclast...
- 11From: Breast Cancer Research. (Vol. 12, Issue 6) Peer-ReviewedThere is increasing evidence of anti-tumour effects of bisphosphonates from pre-clinical studies, supporting a role for these drugs beyond their traditional use in treatment of cancer-induced bone disease. A range of...